L&K Biomed Ltd. (KOSDAQ:156100)
South Korea
· Delayed Price · Currency is KRW 6,190.00
-120.00 (-1.90%)
At close: Mar 31, 2025, 3:30 PM KST
L&K Biomed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 36,092 | 29,905 | 19,767 | 15,373 | 19,356 | Upgrade
|
| Other Revenue | - | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 36,092 | 29,905 | 19,767 | 15,373 | 19,356 | Upgrade
|
| Revenue Growth (YoY) | 20.69% | 51.28% | 28.59% | -20.58% | -27.16% | Upgrade
|
| Cost of Revenue | 5,950 | 4,227 | 4,975 | 8,019 | 5,899 | Upgrade
|
| Gross Profit | 30,142 | 25,678 | 14,792 | 7,354 | 13,457 | Upgrade
|
| Selling, General & Admin | 22,201 | 20,967 | 24,261 | 19,647 | 13,696 | Upgrade
|
| Research & Development | 2,053 | 1,329 | 1,369 | 1,358 | 977.97 | Upgrade
|
| Operating Expenses | 27,064 | 23,644 | 27,530 | 22,634 | 17,315 | Upgrade
|
| Operating Income | 3,078 | 2,034 | -12,738 | -15,280 | -3,859 | Upgrade
|
| Interest Expense | -2,681 | -2,002 | -2,206 | -1,380 | -1,145 | Upgrade
|
| Interest & Investment Income | 589.61 | 384.99 | 219.84 | 107.61 | 127.55 | Upgrade
|
| Earnings From Equity Investments | -300 | -1,172 | -1,199 | -556.16 | -420.88 | Upgrade
|
| Currency Exchange Gain (Loss) | 7,560 | 740.73 | 1,961 | 2,301 | -1,707 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,621 | -330.56 | -2,027 | 4,630 | 639.47 | Upgrade
|
| EBT Excluding Unusual Items | 9,866 | -343.96 | -15,989 | -10,178 | -6,365 | Upgrade
|
| Gain (Loss) on Sale of Investments | 75.14 | 49.41 | - | 1,684 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 254.5 | 16.24 | -65.73 | 220.44 | -519.34 | Upgrade
|
| Asset Writedown | - | -16.8 | -243.71 | -623.87 | -2,355 | Upgrade
|
| Other Unusual Items | -380.94 | -6,173 | - | - | - | Upgrade
|
| Pretax Income | 9,815 | -6,468 | -16,299 | -8,897 | -9,239 | Upgrade
|
| Income Tax Expense | 663.59 | -1,229 | -65.76 | 4,749 | 1,433 | Upgrade
|
| Earnings From Continuing Operations | 9,151 | -5,239 | -16,233 | -13,646 | -10,672 | Upgrade
|
| Minority Interest in Earnings | 591.77 | 3,372 | 2,608 | 3,978 | -43.26 | Upgrade
|
| Net Income | 9,743 | -1,867 | -13,625 | -9,669 | -10,715 | Upgrade
|
| Net Income to Common | 9,743 | -1,867 | -13,625 | -9,669 | -10,715 | Upgrade
|
| Shares Outstanding (Basic) | 20 | 16 | 13 | 13 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 16 | 13 | 13 | 12 | Upgrade
|
| Shares Change (YoY) | 33.94% | 21.21% | 0.07% | 12.57% | 14.15% | Upgrade
|
| EPS (Basic) | 489.00 | -115.00 | -1017.14 | -722.29 | -901.11 | Upgrade
|
| EPS (Diluted) | 448.00 | -115.00 | -1017.14 | -722.29 | -901.11 | Upgrade
|
| Free Cash Flow | -8,015 | -3,417 | -6,684 | -10,501 | -2,721 | Upgrade
|
| Free Cash Flow Per Share | -368.54 | -210.46 | -498.99 | -784.49 | -228.82 | Upgrade
|
| Gross Margin | 83.52% | 85.87% | 74.83% | 47.84% | 69.52% | Upgrade
|
| Operating Margin | 8.53% | 6.80% | -64.44% | -99.40% | -19.94% | Upgrade
|
| Profit Margin | 27.00% | -6.24% | -68.93% | -62.90% | -55.36% | Upgrade
|
| Free Cash Flow Margin | -22.21% | -11.43% | -33.81% | -68.31% | -14.06% | Upgrade
|
| EBITDA | 5,650 | 4,347 | -10,436 | -13,555 | -770.01 | Upgrade
|
| EBITDA Margin | 15.65% | 14.54% | -52.80% | -88.18% | -3.98% | Upgrade
|
| D&A For EBITDA | 2,572 | 2,313 | 2,302 | 1,725 | 3,089 | Upgrade
|
| EBIT | 3,078 | 2,034 | -12,738 | -15,280 | -3,859 | Upgrade
|
| EBIT Margin | 8.53% | 6.80% | -64.44% | -99.40% | -19.94% | Upgrade
|
| Effective Tax Rate | 6.76% | - | - | - | - | Upgrade
|
| Advertising Expenses | 227.72 | 130.35 | 176.7 | 178.07 | 68.79 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.